Upload
open-science-summit
View
440
Download
2
Embed Size (px)
DESCRIPTION
Citation preview
@ANDREWHESSELJULY 31 02010
a drug company for everyone
PINK ARMY COOPERATIVE
http://ilovebacteria.com/Images/bacterialcell.jpg http://i.dell.com/images/global/products/314x314/desktop-studio-mini-left-314.jpg
COMPILE
DESIGN
design/build/design/build/test cycletest cycle
EXECUTE
TEST
applications
David Appleyard
CANCER
CANCER R&D IS
Evolutionary distance
~ 4 billion yearstwo completely different species, far
removed,and bacteria are clonal
many chemical compounds have antimicrobial activity without seriously harming human cells
Evolutionary distance
max: patient’s agecancer cells are same species,
only recently diverged, and every divergence is unique, cells
continue to degrade over time (mixed)
photo by billy hunt
christa slotboom
TARGETING FAST GROWING CELLS IS SO 1950there are plenty of normal cells that grow fast too, making treatments
needlessly harsh
ONE-SIZE-FITS-ALL DRUGMAKING IS ILLOGICALeach person’s DNA is different, their mutations are different, cancers are of
mixed cell types
CANCER RESEARCHERS DON’T MAKE DRUGS drug companies make drugs
A LOT OF RESEARCH ISN’T USEFUL there appears to be a near-infinite number of paths to cancer
CHANGE IS HARDcancer is industry with tremendous inertia
THE IDEAL THERAPEUTIC
specific to the cancergentle
effectivemade quicklyinexpensive
http://www.nature.com/horizon/chemicalspace/background/images/odyssey-f1.jpg
Scientists
newdrug X
shareholders
Lawyers
MANUFACTURERS
clinical trials
Economists
physicians
Insurance companie
s
geneticists
system is inherently limitedrequires blockbustersunable to accelerate
RISK vs BENEFIT (n>1)
STATISTICAL ANALYSIS OF POPULATIONSrequires large markets failure is expensive politicalslow
RISK vs BENEFIT (n=1)
no statistics – just direct observationsrisk benefit analysis always an individual decision
?
isolate and
analyzedesign build test
failures
provide and
evaluate
SYNTHETIC BIOLOGY BIOFAB
results
COOPERATIVE
data sharing
aims to bring together researchers, developers, cancer sufferers and supporters in a self-funded,
open-source therapeutic venture
goal:not a new drug, but a completely new way
of making drugs
one that can accelerate and improve over time
a significant step towards faster, better, cheaper cancer drugs
+ =
diagnostics today, treatments tomorrow
pinkarmy.orgjoin us